118 related articles for article (PubMed ID: 8294050)
1. DNA-topoisomerase I and II: biologic features and their role in drug resistance.
Russo D; Marie JP; Delmer A; Zhou D; Suberville AM; Baccarani M; Zittoun R
Haematologica; 1993; 78(4):201-7. PubMed ID: 8294050
[No Abstract] [Full Text] [Related]
2. Mechanisms of resistance to drugs that inhibit DNA topoisomerases.
Beck WT; Danks MK
Semin Cancer Biol; 1991 Aug; 2(4):235-44. PubMed ID: 1655118
[TBL] [Abstract][Full Text] [Related]
3. [Recent progress in the study of the mechanism of resistance to DNA topoisomerase inhibitors].
Ishida R; Andoh T
Gan To Kagaku Ryoho; 1994 Jun; 21(7):952-61. PubMed ID: 8002633
[TBL] [Abstract][Full Text] [Related]
4. [Inhibitors of DNA topoisomerases].
Andoh T
Gan To Kagaku Ryoho; 1997 Sep; 24(11):1526-35. PubMed ID: 9309151
[TBL] [Abstract][Full Text] [Related]
5. Topoisomerase-targeting antitumor drugs: mechanisms of cytotoxicity and resistance.
Liu LF; D'Arpa P
Important Adv Oncol; 1992; ():79-89. PubMed ID: 1316311
[No Abstract] [Full Text] [Related]
6. Alkylator resistance in human B lymphoid cell lines: (2). Increased levels of topoisomerase II expression and function in a melphalan-resistant B-CLL cell line.
Pu QQ; Bezwoda WR
Anticancer Res; 2000; 20(4):2569-78. PubMed ID: 10953328
[TBL] [Abstract][Full Text] [Related]
7. Drug resistance to DNA topoisomerase I and II inhibitors in human leukemia, lymphoma, and multiple myeloma.
Valkov NI; Sullivan DM
Semin Hematol; 1997 Oct; 34(4 Suppl 5):48-62. PubMed ID: 9408961
[TBL] [Abstract][Full Text] [Related]
8. DNA topoisomerases and topoisomerase inhibitors.
Giaccone G
Pathol Biol (Paris); 1994 Apr; 42(4):346-52. PubMed ID: 7808789
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxic mechanism of XK469: resistance of topoisomerase IIbeta knockout cells and inhibition of topoisomerase I.
Snapka RM; Gao H; Grabowski DR; Brill D; Chan KK; Li L; Li GC; Ganapathi R
Biochem Biophys Res Commun; 2001 Feb; 280(4):1155-60. PubMed ID: 11162648
[TBL] [Abstract][Full Text] [Related]
10. DNA topoisomerase dysfunction: a new goal for antitumor chemotherapy.
Smith PJ
Bioessays; 1990 Apr; 12(4):167-72. PubMed ID: 2159289
[TBL] [Abstract][Full Text] [Related]
11. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
[TBL] [Abstract][Full Text] [Related]
12. Analysis of eukaryotic DNA topoisomerases and topoisomerase-directed drug effects.
Boege F
Eur J Clin Chem Clin Biochem; 1996 Nov; 34(11):873-88. PubMed ID: 8960461
[TBL] [Abstract][Full Text] [Related]
13. Effect of the anticancer drug oracin on mouse liver topoisomerases I and II.
Stuchlík S; Turna J; Miko M
J Pharm Pharmacol; 2005 May; 57(5):657-9. PubMed ID: 15901355
[TBL] [Abstract][Full Text] [Related]
14. Differential cytotoxic pathways of topoisomerase I and II anticancer agents after overexpression of the E2F-1/DP-1 transcription factor complex.
Hofland K; Petersen BO; Falck J; Helin K; Jensen PB; Sehested M
Clin Cancer Res; 2000 Apr; 6(4):1488-97. PubMed ID: 10778981
[TBL] [Abstract][Full Text] [Related]
15. Novel antitumor indenoindole derivatives targeting DNA and topoisomerase II.
Bal C; Baldeyrou B; Moz F; Lansiaux A; Colson P; Kraus-Berthier L; Léonce S; Pierré A; Boussard MF; Rousseau A; Wierzbicki M; Bailly C
Biochem Pharmacol; 2004 Nov; 68(10):1911-22. PubMed ID: 15476662
[TBL] [Abstract][Full Text] [Related]
16. Acetyl-11-keto-beta-boswellic acid induces apoptosis in HL-60 and CCRF-CEM cells and inhibits topoisomerase I.
Hoernlein RF; Orlikowsky T; Zehrer C; Niethammer D; Sailer ER; Simmet T; Dannecker GE; Ammon HP
J Pharmacol Exp Ther; 1999 Feb; 288(2):613-9. PubMed ID: 9918566
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic efficacy of a new topoisomerase I and II inhibitor TAS-103, against both P-glycoprotein-expressing and -nonexpressing drug-resistant human small-cell lung cancer.
Parajuli P; Yano S; Nishioka Y; Nokihara H; Hanibuchi M; Nishimura N; Utsugi T; Sone S
Oncol Res; 1999; 11(5):219-24. PubMed ID: 10608616
[TBL] [Abstract][Full Text] [Related]
18. Syntheses and biological activities (topoisomerase inhibition and antitumor and antimicrobial properties) of rebeccamycin analogues bearing modified sugar moieties and substituted on the imide nitrogen with a methyl group.
Anizon F; Belin L; Moreau P; Sancelme M; Voldoire A; Prudhomme M; Ollier M; Sevère D; Riou JF; Bailly C; Fabbro D; Meyer T
J Med Chem; 1997 Oct; 40(21):3456-65. PubMed ID: 9341921
[TBL] [Abstract][Full Text] [Related]
19. Topoisomerase II expression in normal haemopoietic cells and chronic lymphocytic leukaemia: drug sensitivity or resistance?
McKenna SL; Whittaker JA; Padua RA; Holmes JA
Leukemia; 1993 Aug; 7(8):1199-203. PubMed ID: 8394482
[TBL] [Abstract][Full Text] [Related]
20. DNA topoisomerase II poisons and inhibitors.
Capranico G; Giaccone G; D'Incalci M
Cancer Chemother Biol Response Modif; 1999; 18():125-43. PubMed ID: 10800480
[No Abstract] [Full Text] [Related]
[Next] [New Search]
